• Has over 31 years' experience in drug discovery in the biotech industry

• Served as senior research scientist II at Gilead Sciences, Inc.

• Served as associate director of chemical research at Pharmasset Inc.

• During his career at Pharmasset, Dr. Du, as one of the inventors, participated in the R&D of sofosbuvir, a revolutionary drug for treating hepatitis C which won the Prix Galien Award granted by the Galien Foundation in 2014. Cell has commented that sofosbuvir's contribution to the cure of HCV is regarded as one of the most significant public health accomplishments of our generation

• In Jan. 2012, Gilead Sciences, inc. completed the acquisition of Pharmasset Inc. for about USD 11.2 billion, and thereby obtained sofosbuvir

• Recognized as“State Specially Recruited Experts”by the PRC government

• Has published 60 academic papers and participated in the invention of more than 300 patents registered worldwide, of which 40 patents had been licensed in the United States

• Has over 31 years of experience in R&D, BD and management in the biopharmaceutical industry

• Served as the vice president of CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited, and the vice president of Qilu Pharmaceutical Co., Ltd.

• Served as the Asia head of external innovation for endocrine and cardiovascular system at the Lilly China R&D Center of Eli Lilly and Company

• Served as director of external collaborative drug discovery projects at Merck Sharp & Dohme Corp. and director of medicinal chemistry at Metabasis Therapeutics, Inc.

• Participated in the R&D of various drugs and drug candidates for clinical use, including a first generation and a second generation FBPase inhibitor for the treatment of type II diabetes

• Has over 32 years of experience in pharmacology research and pharmaceutical industry, particularly in oncology, led or supported multiple NDA programs for innovative drugs, most notably Loncastuximab tesirine, a CD-19 ADC for lymphoma, Abivertinib, an EGFR inhibitor for lung cancer, Erdafitinib, an FGFR inhibitor for urothelial cancer, and Dasatinib, a BCR-ABL inhibitor for leukemia

• Received his doctor degree from the University of North Carolina at Chapel Hill

• Served as a senior director at the department of translational medicine and clinical pharmacology in Daiichi Sankyo; served as a director of oncology R&D and a senior leadership team member of experimental medicine and early development at Johnson & Johnson

• Held key leadership positions in certain famous pharmaceutical enterprises including Roche, Bristol-Myers Squibb, etc., with a wealth of experience in translational medicine, clinical development and executive management

• Has over 30 years of experience in the clinical and medicine field

• Served at the University of Virginia Health System in the United States, responsible for medical research and clinical practice

• Served as a physician and director of the International Medical Center at Shenzhen VISTA-SK International Medical Co., Ltd., where he was primarily responsible for providing clinical treatment

• Published 15 high-quality academic papers in international authoritative academic journals and holds multiple invention patents

• Has over 23 years of experience in novel drug R&D; with extensive expertise in novel drug development

• Former Vice General Manager at Shanghai Yishi Medical Technology Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, where he was primarily responsible for R&D of small-molecule novel drugs

• Former Executive Director of the Medicinal Chemistry Department at Adlai Nortye Biopharma Co., Ltd.

• Served as Research Fellow at Vertex, Pharmaceuticals, Inc., U.S., for 17 years, where he was primarily responsible for design and synthesis of novel drugs

• Has over ten years of experience in corporate management

• Successively served as a deputy director and director of general office at Henan Fenglin Industrial Group Co., Ltd., primarily responsible for its administrative management and public relations

• Assigned by Henan Fenglin to serve as the general manager of Henan Jiayuan Dairy Co., Ltd., where he was primarily responsible for its overall operational management. During his tenure in Henan Jiayuan, served as a director, legal representative and/or sole proprietor for nine compound retail stores of Henan Jiayuan

• Served as the assistant to the chairman of the board and the deputy general manager of Xingyu Zhongke